Unlocking the Potential of Ribosomal Protein S17 Pseudogene 6 as a Drug Target or Biomarker

Target Name: RPS17P6

NCBI ID: G391130

RPS17P6

Other Name(s): Ribosomal protein S17 pseudogene 6 | ribosomal protein S17 pseudogene 6 | RPS17_1_116

Unlocking the Potential of Ribosomal Protein S17 Pseudogene 6 as a Drug Target or Biomarker

Introduction

Ribosomal protein S17 (RPS17) is a key regulator of protein synthesis in eukaryotic cells, responsible for ensuring the accuracy and efficiency of translation of mRNAs into functional proteins. The protein is composed of 21 kDa chains and is expressed in all eukaryotic cells. RPS17 plays a crucial role in preventing errors in protein synthesis due to changes in the stability or quality of the mRNAs it encounters. The stability of mRNAs is influenced by various factors, including translation efficiency, folding, and post-translational modification (PTM). RPS17 is Known to play a vital role in these processes and is often targeted by post-translational modifications, such as phosphorylation and ubiquitination, which can alter its stability and localization.

Recent studies have identified RPS17 as a promising drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The discovery of RPS17 as a drug target or biomarker is of great interest due to its potential for targeting new therapeutic approaches in these diseases. In this article, we will explore the biology of RPS17, its functions in eukaryotic cells, its potential drug targets, and its role as a biomarker for disease diagnosis and treatment.

Biography of Ribosomal Protein S17 Pseudogene 6

Ribosomal protein S17 pseudogene 6 (RPS17P6) is a gene that encodes a protein of 21 kDa chains, which is expressed in all eukaryotic cells. The protein is highly conserved across various species, with only minor differences in the amino acid sequences. RPS17P6 is predominantly localized to the endoplasmic reticulum (ER) and cytoplasm, but is also found in the nucleus in a subcellular fraction.

Functional Characterization of RPS17P6

RPS17P6 is a key regulator of protein synthesis in eukaryotic cells. It functions as a chaperone protein, where it helps to ensure the accuracy and efficiency of translation of mRNAs into functional proteins. RPS17P6 does this by interacting with the mRNA and interacting with the ribosome to prevent errors in protein synthesis due to changes in the stability or quality of the mRNAs.

RPS17P6 is involved in various cellular processes, including cell growth, apoptosis, and translation of new proteins. It is known to play a crucial role in preventing errors in protein synthesis that can result from changes in the stability or quality of mRNAs. RPS17P6 has been shown to interact with various cellular components, including the ribosome, tRNA, and microtubules of the mitotic spindle.

Drug Targets for RPS17P6

The discovery of RPS17P6 as a drug target has great potential for targeting new therapeutic approaches in various diseases. RPS17P6 has been shown to be a potential drug target for cancer, neurodegenerative diseases, and autoimmune disorders.

1.Cancer

RPS17P6 has been shown to be involved in various cellular processes that are crucial for cancer development. It has been shown to play a role in the regulation of cell cycle progression, apoptosis, and angiogenesis. RPS17P6 has also been shown to interact with various oncogenic signaling pathways, including the TGF-β pathway.

2. Neurodegenerative Diseases

RPS17P6 has been shown to be involved in the regulation of protein synthesis in neurodegenerative diseases. It has been shown to play a role in the regulation of neurotransmitter synthesis and degradation, as well as

Protein Name: Ribosomal Protein S17 Pseudogene 6

The "RPS17P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS17P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets